CJC-1295 No DAC: Exploring GHRH Receptor Signaling In Vitro

How can a small change in peptide structure change the questions researchers ask in a cell-based experiment?

CJC-1295 no DAC offers an interesting example. Its name is frequently used alongside Modified GRF(1–29), but understanding the material requires more than recognizing a label. The peptide sequence, chemical modifications, and assay model all matter.

This article focuses exclusively on in vitro research: what the no-DAC designation means, how GHRH-receptor signaling can be investigated in cultured cells, and why closely related peptides should be evaluated separately.

What Is CJC-1295 No DAC?

CJC-1295 no DAC is a catalog name commonly associated with Modified GRF(1–29), a synthetic, modified 29-amino-acid analogue of the growth hormone-releasing hormone fragment GHRH(1–29).

The no-DAC structure described in the FDA’s chemical characterization contains substitutions at positions 2, 8, 15, and 27. It lacks the additional albumin-reactive unit associated with the DAC-bearing molecule. [1]

For laboratory work, the name should therefore be treated as a starting point for identification. Researchers should confirm the sequence, terminal modifications, and chemical form of the actual reagent.

A familiar name does not replace a defined molecular identity.

What Does “No DAC” Mean?

DAC refers to the drug affinity complex associated with the albumin-binding design of CJC-1295.

The original 2005 CJC-1295 publication described a substituted GRF(1–29) scaffold with an added reactive lysine derivative at its C terminus. The work included experiments involving albumin conjugates and cultured cells. [2]

That added chemistry distinguishes the DAC-bearing construct from the no-DAC peptide.

For an in vitro comparison, the important question is not simply which label appears on a vial. It is whether the tested materials have the same sequence, reactive groups, and conjugation state.

Results obtained with a DAC-bearing or albumin-conjugated molecule should not automatically be assigned to a no-DAC reagent.

Why the GHRH Receptor Matters in Cell Research

GHRH stands for growth hormone-releasing hormone; GRF is another name used in this research literature.

The GHRH receptor provides a useful example of how researchers connect peptide recognition with an intracellular response.

In a foundational receptor-expression study, researchers introduced the cloned receptor into COS cells. They observed specific GHRH binding and an increase in intracellular cyclic AMP, or cAMP, following GHRH exposure. A receptor antagonist blocked both the binding and the second-messenger response. [3]

This study supports the use of receptor-expressing cell systems to investigate GHRH signaling. It is not a direct test of every modified GHRH analogue sold under a similar name.

For CJC-1295 no DAC research, that distinction keeps pathway background separate from evidence about a particular reagent.

Binding and Signaling Are Different Measurements

A receptor-binding experiment asks whether a compound interacts with a receptor under the conditions tested.

A functional experiment asks what happens after that interaction.

These are related questions, but they are not interchangeable. A binding result alone does not establish the size, timing, or specificity of a signaling response.

For a cell-based GHRH-receptor investigation, researchers might compare:

• Receptor-binding measurements.
• Intracellular cAMP responses.
• The timing of a measured response.
• Results in receptor-expressing and appropriate control cells.
• Cell viability alongside the signaling endpoint.

The best endpoint depends on the experimental question. Combining complementary measurements can make a proposed mechanism easier to evaluate.

Why cAMP Is an Informative Readout

cAMP is an intracellular second messenger. In the receptor-expression experiments described above, it provided a measurable functional response to GHRH. [3]

That makes cAMP relevant background for designing GHRH-receptor assays.

However, detecting a cAMP change does not, by itself, identify the receptor responsible. The earlier receptor study is informative partly because it paired signaling measurements with receptor-expression and antagonist experiments. [3]

When reading a CJC-1295 no-DAC paper, ask whether the experiment establishes a receptor-dependent response or simply reports a change in a downstream signal.

In Vitro Questions Worth Separating

The following examples describe research questions, rather than a validated protocol for a particular product.

Why Culture Conditions Belong in the Discussion

A peptide result becomes more informative when the surrounding conditions are documented.

Cell model, receptor expression, medium composition, exposure duration, and the presence of serum proteins are all details readers should examine when comparing studies.

For this peptide family, documenting whether albumin is present and whether a reagent contains albumin-reactive chemistry is particularly relevant to interpreting the material being tested. The original CJC-1295 work explicitly investigated albumin conjugation. [2]

A stability measurement in one solution should remain specific to that solution and the analytical method used. It should not be converted into a universal statement about behavior in every cell-culture system.

Reading a Certificate of Analysis for Research Context

A certificate of analysis can help researchers connect a tested sample to a defined lot, but its usefulness depends on the information provided.

When evaluating documentation, distinguish among:

• Identity: what analytical evidence supports the assigned molecule?
• Purity: which method was used, and what does its reported percentage represent?
• Content: was the amount of peptide independently quantified?
• Traceability: can the report be connected to the material being studied?

These are separate questions. A reported purity percentage is not a receptor-activity measurement, and a product name alone does not establish sequence identity.

Frequently Asked Questions

Is CJC-1295 no DAC the same as Modified GRF(1–29)?

The names are commonly used together in catalogs. Confirm the sequence and chemical modifications before treating two materials as equivalent.

Is the DAC-bearing molecule interchangeable with the no-DAC peptide?

No. Their chemical structures differ. A study must identify which material it tested before its findings can be applied to another experiment. [1,2]

Can any cultured cell line be used to examine GHRH-receptor signaling?

The model must suit the question. For receptor-specific work, researchers need evidence that the relevant receptor is present and functional, together with appropriate controls.

Does a blend establish enhanced signaling?

No. A mixture needs its own controlled investigation. Measurements from individual components do not establish an interaction between them.

Explore Cell-Based Peptide Research With Lyos Labs

CJC-1295 no DAC illustrates why peptide research begins with molecular identity and a clearly defined experimental question.

Understanding the difference between binding, signaling, and reagent stability helps researchers describe their observations precisely—and makes comparisons between cell-based studies more useful.

At Lyos Labs, our educational articles explore peptide science through defined laboratory models, published research, and careful interpretation of experimental evidence.

For research use only. Intended solely for in vitro laboratory research. Not for human or veterinary use.

References

1. U.S. Food and Drug Administration. (2024). CJC-1295-related substances: chemical characterization, Section II.A. Cited here for molecular identity and structural distinctions.
2. Jetté L, et al. (2005). Original CJC-1295 scaffold and albumin-bioconjugation study. Endocrinology, 146(7), 3052–3058. doi:10.1210/en.2004-1286. Discussion above is limited to molecular design and in vitro research context.
3. Gaylinn BD, et al. (1993). GHRH-receptor cloning and expression study. Molecular Endocrinology, 7(1), 77–84. doi:10.1210/mend.7.1.7680413.